Valuation : Cerus Corporation

Market Cap 532M 459M 432M 393M 740M 50.49B 744M 5.1B 1.99B 25.68B 2B 1.95B 85.17B P/E 2026 *
-75.4x
P/E 2027 * -264x
Enterprise Value 537M 463M 436M 397M 747M 50.97B 751M 5.15B 2.01B 25.93B 2.02B 1.97B 85.97B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.91x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.14%
1 week-4.04%
Current month-1.14%
1 month+21.40%
3 months-8.10%
6 months+3.16%
Current year+26.70%
1 week 2.56
Extreme 2.56
2.79
1 month 2.06
Extreme 2.065
3.08
Current year 1.62
Extreme 1.62
3.47
1 year 1.17
Extreme 1.17
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 30/06/2026
Chief Tech/Sci/R&D Officer 82 30/06/2015
Director of Finance/CFO 54 03/05/2009
Director TitleAgeSince
Chairman 59 15/03/2026
Director/Board Member 72 23/03/2014
Director/Board Member 51 30/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-30,000 0.0150%
16/07/26 Sell

Chief Executive Officer

-16,666 0.0083%
01/07/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-4.04%+105.51%+35.94% 532M
-1.98%-3.99%-18.60%+11.58% 124B
+0.71%-1.11%-22.63%0.00% 12.11B
-1.59%-2.59%+88.08%+135.95% 10.59B
+1.11%+2.67%-51.62%-70.04% 4.16B
-1.07%-8.97%-24.70%+36.73% 2.52B
+0.53%+0.62% - - 2B
-2.33%+0.74%-34.91%-74.24% 1.82B
-0.07%-1.70%-18.18%-21.31% 1.6B
Average -0.71%-2.12%+2.87%+6.83% 17.73B
Weighted average by Cap. -1.65%-1.40%-12.48%+16.05%

Financials

2026 *2027 *
Net sales 249M 215M 202M 184M 346M 23.64B 348M 2.39B 930M 12.02B 935M 915M 39.87B 272M 234M 220M 201M 377M 25.77B 379M 2.6B 1.01B 13.11B 1.02B 997M 43.47B
Net income -8.77M -7.56M -7.11M -6.48M -12.19M -832M -12.25M -84.09M -32.73M -423M -32.91M -32.2M -1.4B -1.67M -1.44M -1.35M -1.23M -2.32M -158M -2.33M -15.99M -6.22M -80.46M -6.26M -6.12M -267M
Net Debt 5M 4.31M 4.06M 3.7M 6.95M 475M 6.99M 47.96M 18.67M 241M 18.77M 18.37M 800M -13M -11.21M -10.55M -9.61M -18.07M -1.23B -18.17M -125M -48.54M -628M -48.81M -47.75M -2.08B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
01/09/26 US$2.610 -1.14% 1,083,867
31/08/26 US$2.640 -0.38% 1,321,177
28/08/26 US$2.650 -2.57% 1,683,565
27/08/26 US$2.720 -0.73% 810,572
26/08/26 US$2.740 +0.74% 1,103,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.640USD
Average target price
5.125USD
Spread / Average Target
+94.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock